Global trends in clinical studies of ivermectin in COVID-19
THE JAPANESE JOURNAL OF ANTIBIOTICS
Mar. 2021
▻http://jja-contents.wdc-jp.com/pdf/JJA74/74-1-open/74-1_44-95.pdf
Conclusion
The effective concentration of #ivermectin against #SARS-CoV-2 in an in vitro experiment by Caly et al. is as high as 2 μM; in clinical practice, it is necessary to administer tens of times the normal dose in order to obtain such a blood concentration. Therefore, there are opinions from the IDSA98) and others that the therapeutic effect of #COVID-19 cannot be expected by the administration of the normal dose of ivermectin.
However, in actual medical practice, there are many study reports demonstrating that the administration of a normal dose does indeed show a clinical response. As of the 27th of February 2021, the results of 42 clinical studies worldwide have undergone meta-analysis and concluded that ivermectin is effective in the treatment and prevention of COVID-19. In the UK, a consensus-based recommendation by 75 healthcare professionals from 17 countries around the world has been carried out and submitted to the WHO to further encourage the issuance of guidelines for the use of ivermectin in the treatment and prevention of COVID-19. We must consider why such a discrepancy is occurring.